Centromere IgG Antibody, in Visit Clinic

Centromere IgG antibodies are a subtype of antinuclear antibodies that target centromere proteins (CENP) of chromosomes. Detected by immunofluorescence or ELISA, IgG anticentromere positivity strongly suggests limited cutaneous systemic sclerosis (CREST) and can predict features like pulmonary hypertension and digital ischemia. They are useful diagnostic and prognostic markers in autoimmune connective tissue disease evaluation.

A positive IgG antibody test means your immune system has previously encountered the specific pathogen or vaccine and produced IgG antibodies. It usually indicates past infection or immunization and often suggests some degree of immunity, though it doesn’t necessarily rule out current infection or guarantee complete protection. Timing matters—IgG appears later and can persist for months or years depending on the disease.

Anticentromere antibodies are most strongly linked to systemic sclerosis—especially the limited cutaneous (CREST) form—and to features like Raynaud’s phenomenon and pulmonary hypertension. They can also be present in primary biliary cholangitis and, less commonly, in other autoimmune diseases (eg, Sjögren’s syndrome, systemic lupus erythematosus) or overlap syndromes, where they help indicate disease subset and prognosis.

A positive anti‑centromere antibody result occurs when the immune system produces antibodies targeting centromere proteins. It is most commonly associated with limited cutaneous systemic sclerosis (CREST syndrome), and can also appear in other autoimmune conditions (e.g., primary biliary cholangitis) or rarely in healthy people. Genetic susceptibility and environmental triggers likely contribute; clinicians use it to support diagnosis and predict features like pulmonary hypertension.

Normal (negative) anti‑centromere antibody results depend on method and lab. Common cutoffs: ELISA — <20 U/mL (negative), 20–40 borderline, >40 U/mL (positive); indirect immunofluorescence — titers <1:40 (often <1:80) usually negative, titers ≥1:80 considered significant. Higher titers can indicate limited cutaneous systemic sclerosis or other autoimmune conditions; discuss results with your clinician.

Common symptoms of scleroderma include thickening, hardening and tightening of the skin, especially on fingers and face; Raynaud’s phenomenon (cold, numb fingers); swollen, stiff or painful joints; fingertip ulcers and telangiectasias; digestive problems such as reflux and difficulty swallowing; and internal organ involvement causing shortness of breath, cough, or impaired kidney function. Fatigue and reduced hand mobility are also frequent.